REPLIMUNE GROUP INC. - COMMON STOCK

Replimune Presents Initial RP1 Data from the ARTACUS Clinical Trial at the 2023 American Transplant Congress (ATC) Meeting

06 Jun 2023 10:00:00 By Nasdaq GlobeNewswire

Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors

05 Jun 2023 08:00:00 By Nasdaq GlobeNewswire

Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

03 Jun 2023 14:15:00 By Nasdaq GlobeNewswire

Replimune to Present at the Jefferies Global Healthcare Conference

01 Jun 2023 16:01:00 By Nasdaq GlobeNewswire

Replimune to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

25 May 2023 17:00:00 By Nasdaq GlobeNewswire

Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update

18 May 2023 08:00:00 By Nasdaq GlobeNewswire

Replimune to Participate in the Piper Sandler Spring Biopharma Symposium

09 May 2023 08:00:01 By Nasdaq GlobeNewswire

Replimune to Present at Two Upcoming Investor Conferences

08 Mar 2023 08:00:01 By Nasdaq GlobeNewswire

Replimune Reports Fiscal Third Quarter Financial Results and Provides Corporate Update

09 Feb 2023 08:00:01 By Nasdaq GlobeNewswire

Replimune to Present at the Virtual SVB Securities Global Biopharma Conference

07 Feb 2023 08:00:02 By Nasdaq GlobeNewswire

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Jan 2023 08:05:00 By Nasdaq GlobeNewswire

Replimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer

04 Jan 2023 08:00:01 By Nasdaq GlobeNewswire

Replimune to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 08:00:01 By Nasdaq GlobeNewswire

Replimune Announces Pricing of Public Offering

08 Dec 2022 21:04:34 By Nasdaq GlobeNewswire

Replimune Announces Proposed Public Offering

07 Dec 2022 16:04:04 By Nasdaq GlobeNewswire

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

07 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma

07 Dec 2022 06:30:00 By Nasdaq GlobeNewswire

Replimune to Present at the Piper Sandler 34th Annual Healthcare Conference

23 Nov 2022 08:00:00 By Nasdaq GlobeNewswire

Replimune to Host Virtual Investor Event on December 7, 2022

22 Nov 2022 08:00:01 By Nasdaq GlobeNewswire

Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update

03 Nov 2022 08:00:03 By Nasdaq GlobeNewswire